press releases

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that its Chief Commercial Officer, Peter Melnyk, will be leaving the company to pursue other interests. Mr. Melnyk will continue his employment with the company until March 15, 2017 to ensure a smooth transition. “I want to thank… Read More

Continued growth in active patients with 1,091 active patients at December 31, 2016, an increase of 80 percent from December 31, 2015, and 11 percent from September 30, 2016 Fourth quarter 2016 net revenues of $30.2 million, reflecting 144 percent growth versus fourth quarter 2015 and 40… Read More

The trial will test the efficacy and safety of TTFields at 150 kHz in combination with two of the current standard of care treatments, immune checkpoint inhibitors or docetaxel ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in the BIO 2017 CEO & Investor Conference on Feb. 13, 2017, in New York City. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Mr. Doyle’s… Read More

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in Noble Capital Markets’ 13th Annual Investor Conference on Jan. 31, 2017, in Boca Raton, Florida. Ashley Cordova, Novocure’s Vice President of Finance and Investor Relations, will speak on behalf of the company and address questions from… Read More

Globally, nearly 800 medical institutions can prescribe Optune to glioblastoma patients ST. HELIER, Jersey–(BUSINESS WIRE)– Physicians at 500 cancer treatment centers in the U.S. have been certified to prescribe Novocure’s (NASDAQ:NVCR) Optune® to newly diagnosed and recurrent glioblastoma (GBM) patients. Optune is Novocure’s wearable, portable,… Read More

1,091 active patients at Dec. 31, 2016, an increase of 80 percent versus Dec. 31, 2015 January 10, 2017 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR), a commercial-stage oncology company developing a proprietary therapy for solid tumors, will provide a business update… Read More

January 10, 2017 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that it will report financial results for the fourth quarter and full year 2016 on Thursday, Feb. 23, 2017, before the open of U.S.-based financial markets. Novocure management will host a conference call… Read More

Optune is the first MHLW-approved therapy in more than a decade to demonstrate statistically and clinically significant extension of survival in newly diagnosed GBM patients December 19, 2016 07:27 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the Japanese Ministry… Read More